Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2011940 | 0.71 | BRD4 (0.39) | BRD4L3MBTL1KMT2AMAPTALDH1A1 | |
| SCHEMBL2014758 | 0.71 | BRD4 (0.39) | BRD4L3MBTL1KMT2AMAPTALDH1A1 | |
| SCHEMBL27380646 | 0.63 | GAA (0.43) | BRD4TSHRGAAUSP2CYP3A4 | |
| SCHEMBL28346386 | 0.62 | GAA (0.42) | BRD4L3MBTL1KMT2AMEN1TSHR | |
| SCHEMBL26754371 | 0.62 | CYP3A4 (0.37) | BRD4L3MBTL1TSHRGAAUSP2 | |
| SCHEMBL26754374 | 0.62 | DAGLA (0.36) | BRD4L3MBTL1TSHRGAAUSP2 | |
| SCHEMBL19930127 | 0.61 | HSD17B10 (0.36) | BRD4KMT2AMEN1TSHRGAA | |
| SCHEMBL3119295 | 0.61 | TSHR (0.69) | L3MBTL1KMT2AMEN1TSHRALDH1A1 | |
| SCHEMBL18916559 | 0.61 | GLS (0.47) | BRD4L3MBTL1TSHRGAAUSP2 | |
| SCHEMBL1623008 | 0.61 | GLS (0.47) | BRD4L3MBTL1TSHRGAAUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | BRD4 2674/4885L3MBTL1 2505/4885KMT2A 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.